Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity

This publication has 34 references indexed in Scilit:

• The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated Patients
  Gynecologic Oncology, 2001
• Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin
  Cancer, 2001
• Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
  Human & Experimental Toxicology, 1999
• Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
  Advanced Drug Delivery Reviews, 1997
• Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non‐cross‐resistant anthracycline annamycin incorporated in liposomes
  International Journal of Cancer, 1995
• Clinical Studies of Liposome-Encapsulated Doxorubicin
  Acta Oncologica, 1994
• Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1993
• Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1989
• 125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo
  Biochemical and Biophysical Research Communications, 1984
• Liposome disposition in vivo
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981